4.7 Article

Heterotypic cell-in-cell structures between cancer and NK cells are associated with enhanced anticancer drug resistance

期刊

ISCIENCE
卷 25, 期 9, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.isci.2022.105017

关键词

-

资金

  1. National Research Foundation of Korea (NRF) - Korean Ministry of Science and Information Technology (MSIT) [NRF-2020R1C1C1012542]
  2. National Research Council of Science & Technology (NST) [CCL22061-100, CAP-18-02-KRIBB]
  3. Korea Food Research Institute
  4. Korea Basic Science Institute [C170100, C170300, K115000]
  5. National Research Council of Science & Technology (NST), Republic of Korea [CAP-18-02-KRIBB, C170300, C170100] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

This study observed heterotypic cell-cell interactions in tumor tissues, showing their association with immune evasion and drug resistance in cancer cells.
The heterotypic CIC structures formed of cancer and immune cells have been observed in tumor tissues. We aimed to assess the feasibility of using heterotypic CICs as a functional biomarker to predict NK susceptibility and drug resistance. The heterotypic CIC-forming cancer cells showed a lower response to NK cyto-toxicity and higher proliferative ability than non-CIC cancer cells. After treatment with anticancer drugs, cancer cells that formed heterotypic CICs showed a higher resistance to anticancer drugs than non-CIC cancer cells. We also observed the formation of more CIC structures in cancer cells treated with anticancer drugs than in the non-treated group. Our results confirm the association between het-erotypic CIC structures and anticancer drug resistance in CICs formed from NK and cancer cells. These results suggest a mechanism underlying immune evasion in heterotypic CIC cancer cells and provide insights into the anticancer drug resis-tance of cancer cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据